Esperion Therapeutics, Inc. Announces Exercise of Underwriters’ Over-Allotment Option for Initial Public Offering
July 11 2013 - 4:00PM
Business Wire
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced that the underwriters of its recently completed initial
public offering (IPO) have exercised in full their option to
purchase an additional 750,000 shares of common stock from Esperion
to cover over-allotments. The sale of the additional shares closed
on July 11, 2013. Including proceeds from the sale of the
additional shares, the net proceeds to Esperion from the IPO are
expected to be $72.8 million after deducting underwriting discounts
and commissions and estimated offering expenses payable by
Esperion.
Credit Suisse and Citigroup acted as joint book-running managers
for the offering. JMP Securities and Stifel acted as
co-managers.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on
June 25, 2013. Copies of the final prospectus relating to the
offering may be obtained by contacting Credit Suisse Securities
(USA) LLC, Attention: Prospectus Department, One Madison Avenue,
New York, NY 10010, by calling toll-free (800) 221-1037, or by
emailing newyork.prospectus@credit-suisse.com; or Citigroup Global
Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, by email at batprospectusdept@citi.com,
or by phone at (800) 831-9146.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
BrewLifeDenise Powell510.703.9491dpowell@brewlife.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024